Skip to main content
. Author manuscript; available in PMC: 2013 Mar 26.
Published in final edited form as: Brain Behav Immun. 2011 Jul 21;25(8):1716–1724. doi: 10.1016/j.bbi.2011.07.227

Figure 2. Inhibition of dexamethasone (DEX)-induced luciferase activity by mouse interferon (mIFN)-alpha is attenuated by cAMP-protein kinase A (PKA) pathway activation in HT22 cells.

Figure 2

HT22 cells stably transfected with the MMTV-luciferase reporter gene construct were grown in 12-well culture plates until 80% confluent. Cells were treated with a combination of mIFN-alpha (1000 U/ml), forskolin (FSK)(10 μM), and/or the selective PKA inhibitor H89 (1 or 10 μM) for 22 hours followed by continued treatment with the same respective combinations plus DEX (50 nM) or vehicle for 2 hours. Luciferase activity was then measured as described in Methods. All conditions were run in triplicate, and values shown are means (±SEM). Results are representative of three independent experiments. * p < 0.05 vs no treatment (all vehicle) condition; † p < 0.05 vs DEX only treatment condition; # p < 0.05 vs mIFN-alpha plus DEX condition; ## p < 0.05 vs mIFN-alpha plus DEX plus forskolin condition; (x0005E;) p < 0.05 vs DEX plus forskolin condition.